Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Liver Trial on Oral Tocotrienol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02581085
Recruitment Status : Recruiting
First Posted : October 20, 2015
Last Update Posted : April 2, 2019
Sponsor:
Collaborator:
Malaysia Palm Oil Board
Information provided by (Responsible Party):
Chandan Sen, Indiana University

Brief Summary:
The purpose of this Phase IIA trial is to validate the outcome observed in the Phase I trial that oral TCT attenuates the rise in MELD over time in patients diagnosed with NAFLD, NASH or chronically infected hepatitis C. Subjects will participate for 3 years. They will be asked to come to 8 total study visits and will receive 6 follow-up phone calls within the 3 years of participation. Subjects will be asked to take 2 study capsules of vitamin E Tocotrienol (200mg) twice a day or 2 placebo capsules twice a day. The study is randomized and study staff will be blinded to randomization.

Condition or disease Intervention/treatment
End Stage Liver Disease Hepatitis C Drug: Tocotrienol Other: Placebo

Detailed Description:

As a safe and natural vitamin, tocotrienol (TCT) stands uniquely poised to treat ~500 million worldwide who suffer from viral hepatitis. Furthermore, for those awaiting liver transplantation, TCT may buy more time until a liver becomes available. The primary purpose of this Phase IIA trial is to validate the outcome observed in the limited sample size Phase I trial (n=6) that oral TCT attenuates the rise in MELD over time in patients with NAFLD, NASH, or Hepatitis C. Outcomes will direct the design of a multi-center Phase IIB trial.

Study participation will last 3 years. Subjects will be seen for an initial visit, at which consent will be obtained and baseline labs drawn, followed by a Randomization visit 2-14 days later after MELD criteria have been confirmed. If the acceptable labs have not been drawn per standard of care to calculate a MELD score within 90 days before the initial visit, the subject will complete the initial visit as planned, but will then return for a repeat lab draw 60 days later to confirm MELD criteria for eligibility before continuing to the randomization visit.

Enrollment occurs when a subject meets all criteria and is randomized into one of the treatment groups. Subjects will then be seen in the research office by research personnel at 1 month, 2 months, 3 months, 6 months, 1 year, 18 months, 2 years, and 3 years. Subjects will receive follow-up phone calls at 9 months, 15 months, 21 months, 27 months, 30 months, and 33 months. Subject compliance with supplements will be closely followed, as compliance is critical for accurate data. Given the small sample size, subjects who are less than 75% compliant at two consecutive study visits will be discontinued from the study. Subjects will be discontinued if their MELD score increases by more than 25% between 2 consecutive visits or if they receive an organ transplant. Subjects will be declared lost to follow-up (LTFU) if a study visit is unable to be scheduled and completed after 4 documented attempts to contact a subject with no response. In this circumstance, a certified letter will be mailed to the subject's last known address; if no response is received, the subject is LTFU. All subjects discontinued or LTFU before the end of 1 year of study participation will be replaced (see protocol to review study visit activities that will occur). At the Randomization Visit, enrolled subjects will be randomized into one of two treatment groups in a 1:1 manner. Group 1: Placebo vehicle; (2) placebo capsules following AM meal, (2) placebo capsules following PM meal Group 2: 800mg TCT; (2) 200mg TCT capsules following AM meal, (2) 200mg TCT capsules following PM meal


Layout table for study information
Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Tocotrienol Against the Progression of End Stage Liver Disease
Estimated Study Start Date : April 2019
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022


Group/Cohort Intervention/treatment
Placebo Vehicle
Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
Other: Placebo
Control study capsule that includes no study product (Vitamin E - Tocotrienol)
Other Name: vehicle

Tocotrienol supplement
Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
Drug: Tocotrienol
Vitamin E is a dietary supplement. Vitamin E is a fat-soluble vitamin that exists in eight different forms. Each form has its own biological activity, which is the measure of potency or functional use in the body. Vitamin E is a dietary antioxidant that assists in maintaining cell integrity. It is obtained from sunflower, safflower, canola, and olive oils; also from many grains, nuts, fruits as well as fatty parts of meats. The tocotrienol form of natural vitamin E is found in rice and cereals but more abundantly in palm oil. Palm oil is an integral part of daily diet in southeastern Asia
Other Name: Vitamin E




Primary Outcome Measures :
  1. Effect of Oral tocotrienols (TCT) on Model for End-Stage Liver Disease (MELD) score [ Time Frame: 3 years ]
    Lab tests including viral load viral, viral genotype, bilirubmin, fibrosure, and INR will be taken at baseline study visit and the last study visit ( Study visit 8 - 3 years) and will calculate MELD scores to see if Oral TCT will significantly attenuate the rise in MELD score over time in patients with End Stage Liver Disease


Biospecimen Retention:   Samples With DNA
Blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
70 patients with hepatitis C cirrhosis
Criteria

Inclusion Criteria:

  • Age 18 years of above, male or female
  • ESLD patients with clinically- diagnosed NAFLD, NASH, or chronically infected with hepatitis C virus (HCV, all genotypes), with amount of virus in the blood greater than 10,000 IU/ml
  • Absence of any other possible cause for liver dysfunction
  • Stable MELD score of at least 8, but no greater than 15 over the past 6 months (+/- 1 month) prior to enrollment
  • Able to speak and understand English
  • Willing and able to provide informed consent
  • Willing and able to return for regularly scheduled research study visits & comply with study requirements

Exclusion Criteria:

  • Rapid deterioration of liver function, over the past 6 months (+/- 1 month) prior to enrollment per study physician determination
  • Hepatocellular carcinoma
  • Positive HIV/ AIDS, or other chronic immunodeficiency
  • Concurrent hepatitis A or B infection
  • Current drug and/or alcohol abuse (per treating physician)
  • Bacterial infection at time of enrollment
  • Daily use of dedicated vitamin E supplementation within the 12 months prior to study participation
  • Platelets <25,000 cells/µL, neutrophils <1000 cells/µL, hemoglobin <8g/dL, total bilirubin >3mg/dL, serum creatinine >2.0mg/dL
  • Women who are pregnant, breastfeeding, or plan to become pregnant during course of study participation (36 months)
  • Other significant comorbidities which limit the subject's life expectancy to less than 36 months
  • Patients receiving medications known to treat Hepatitis C; patients who begin taking these medications during the course of study participation will be dropped.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02581085


Contacts
Layout table for location contacts
Contact: Jennifer Mohnacky, RN 317-278-2715 jmohnack@iu.edu
Contact: Sashwati Roy, Ph.D 3172782706 roysa@iu.edu

Locations
Layout table for location information
United States, Indiana
IU Health Methodist Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Jennifer Mohnacky, RDN    317-278-2715    jmohnack@iu.edu   
Sponsors and Collaborators
Indiana University
Malaysia Palm Oil Board
Investigators
Layout table for investigator information
Principal Investigator: Chandan K Sen, Ph.D The Ohio State University Wexner Medical Center

Publications:

Layout table for additonal information
Responsible Party: Chandan Sen, Professor, Indiana University
ClinicalTrials.gov Identifier: NCT02581085     History of Changes
Other Study ID Numbers: 1807361301
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Chandan Sen, Indiana University:
Tocotrienol
Vitamin E

Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin E
Tocopherols
Tocotrienols
alpha-Tocopherol
Hepatitis C
Liver Diseases
End Stage Liver Disease
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Hepatitis
Digestive System Diseases
Liver Failure
Hepatic Insufficiency
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents